Andranik Hakobyan

Hypertension drug developer Mineralys Therapeutics (MLYS) has filed for a $100M initial public offering.

The biotech company didn’t specify in its filing the price or number of shares to be offered, but indicated in its filing



Source link

Previous articleDollar rises on safe haven bids; yen regains footing By Reuters
Next articleIndian Corporates Seek A Relook At Buyback Tax

LEAVE A REPLY

Please enter your comment!
Please enter your name here